News of Note—TapImmune’s breast cancer combo, IAVI’s HIV vaccine and more

newspaper
In this week's news of note, the DOD grants $11 million for a TapImmune breast cancer study. (PIxabay)

Here is some other vaccine news of note for the week.

> With a grant of $11 million from the U.S. Department of Defense, investigators will test TapImmune’s breast cancer vaccine, TPIV110, in combination with Roche's Herceptin in a phase 2 study. Release

> The International AIDS Vaccine Initiative has started human testing of a novel HIV vaccine designed to initiate a key first step in the generation of broadly neutralizing antibodies. Release

> The University of Montana won a $10 million, five-year contract from the NIH to develop a new universal flu vaccine. Release

> Valneva nabbed FDA approval for an accelerated, seven-day dosing regimen for Japanese encephalitis vaccine Ixiaro. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.